XML 36 R19.htm IDEA: XBRL DOCUMENT v3.25.1
Net Income (Loss) Per Share
 6 Months Ended
Mar. 31, 2025
Earnings Per Share [Abstract]  
Net Income (Loss) Per Share NET INCOME (LOSS) PER SHARE
The following table presents the computation of basic and diluted net income (loss) per share for the three and six months ended March 31, 2025 and 2024.
Three Months Ended March 31,Six Months Ended March 31,
2025202420252024
(in thousands, except per share amounts)
Numerator:
Net income (loss) attributable to Arrowhead Pharmaceuticals, Inc.$370,445 $(125,300)$197,360 $(258,164)
Denominator:
Weighted-average basic shares outstanding (1)
133,363 123,285 129,059 115,307 
Effect of dilutive securities1,121 — 1,206 — 
Weighted-average diluted shares outstanding (1)
134,484 123,285 130,265 115,307 
Basic net income (loss) per share$2.78 $(1.02)$1.53 $(2.24)
Diluted net income (loss) per share$2.75 $(1.02)$1.52 $(2.24)
(1) Includes shares of common stock into which the Avoro Pre-Funded Warrants may be exercised. See Note 6.
The following table sets forth the potentially dilutive securities that have been excluded from the calculation of diluted net income (loss) per share because to include them would be anti-dilutive.
Three Months Ended March 31,Six Months Ended March 31,
2025202420252024
(in thousands)
Options760 595 750 657 
Restricted stock units5,289 3,411 4,567 3,931 
Total6,049 4,006 5,317 4,588